Abramson JS et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early-stage classical Hodgkin lymphoma: Updated results from an ongoing phase 2 study (SGN35-027 Part C). ICML 2023;Abstract 254.
Ansell SM et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med 2022;387(4):310-20. Abstract
Bartlett NL et al. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma. Blood Adv 2023;[Online ahead of print]. Abstract
de Vos S et al. Magrolimab, rituximab and acalabrutinib for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Results from the phase 1 PRISM trial. Blood 2022;140(Suppl 1):6635-7. Abstract
Dreyling M et al. TRIANGLE: Autologous transplantation after rituximab/ibrutinib/ARA-C containing induction in generalized mantel cell lymphoma – A randomized European MCL network trial. ASH 2022;Abstract 1.
Flinn IW et al. ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard of care therapy in patients with relapsed or refractory follicular lymphoma. ASCO 2023;Abstract TPS7579.
Fornecker L-M et al. Brentuximab vedotin plus AVD for first-line treatment of early-stage unfavorable Hodgkin lymphoma (BREACH): A multicenter, open-label, randomized, phase II trial. J Clin Oncol 2022;41(2):327-35. Abstract
Herrera AF et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage(AS) classic Hodgkin lymphoma (HL). ASCO 2023;Abstract LBA4.
Herrera AF et al. Exploratory analysis of factors influencing efficacy and safety of camidanlumab tesirine: Data from the open-label, multicenter, phase 2 study of patients with relapsed or refractory classical Hodgkin lymphoma (R/R cHL). ASH 2022;Abstract 542.
Ito R et al. MCL-135 BRUIN MCL-321, a phase 3 open-label, randomized study of pirtobrutinib versus investigator choice of BTK inhibitor in patients with previously treated, BTK inhibitor naïve mantle cell lymphoma (trial in progress). SOHO 2022;Abstract MCL-135.
Kurtz DM et al. Ultrasensitive circulating tumor DNA (ctDNA) dynamics after autologous CD30.CAR-T cell therapy for relapsed or refractory (r/r) classical Hodgkin lymphoma (CHARIOT trial). ASH 2022;Abstract 984.
Le Gouill S et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: A phase 1/2 trial. Blood 2021;137(7):877-87. Abstract
Lee HJ et al. Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced-stage classical Hodgkin lymphoma: Updated efficacy and safety results from the single-arm phase 2 study (SGN35-027 Part B). ASH 2022;Abstract 314.
Mato A et al. NX-2127-001, a first-in-human trial of NX-2127, a Bruton’s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies. ASH 2022;Abstract 965.
Phillips TJ et al. Safety and efficacy of ABR in pts with TN or R/R MCL: Ph Ib Trial. ASCO 2023;Abstract 7546.
Ruan J et al. Phase 2 trial of acalabrutinib-lenalidomide-rituximab (ALR) with real-time monitoring of MRD in patients with treatment-naïve mantel cell lymphoma. ASH 2022;Abstract 73.
Sehn LH et al. ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell–like (non-GCB) diffuse large B-cell lymphoma (DLBCL). ASCO 2021;Abstract TPS7572.
Shadman M et al. Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: A phase 2, open-label, single-arm study. Lancet Haematol 2023;10(1):e35-45. Abstract
Song Y et al. Zanubrutinib in relapsed/refractory mantel cell lymphoma: Long-term efficacy and safety results from a phase 2 study. Blood 2022;139(21):3148-58. Abstract
Thieblemont C et al. Iberdomide (CC-220) monotherapy or in combination with an anti-CD20 monoclonal antibody as effective therapy in patients with relapsed/refractory lymphoma: Early results from a phase 1/2 study. ASH 2022;Abstract 233.
Tilly H et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351-63. Abstract
Wang ML et al. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantel cell lymphoma. J Clin Oncol 2023;[Online ahead of print]. Abstract
Wang ML et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantel cell lymphoma: Additional patients and extended follo0w-up from the phase 1/2 BRUIN study. ASH 2022;Abstract 4218.
Wang ML et al. Ibrutinib plus bendamustine and rituximab in untreated mantel-cell lymphoma. N Engl J Med 2022;386(26):2482-94. Abstract
Wang M et al. Acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma: Final results from a phase 2 study. Pan Pacific Lymphoma Conference 2021;Abstract 146.
Wang ML et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantel cell lymphoma: The safety run-in of the phase 2 SYMPATICO study. J Hematol Oncol 2021;14(1):179. Abstract
Woyach JA et al. Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated Bruton tyrosine kinase inhibitor for B-cell malignancies: Updated analysis of the open-label phase 1/2 dose-expansion Bellwave-001 study. ASH 2022;Abstract 642.